302550.KQ Remed Co.Ltd
- Market cap
- KRW 68.1B
- P/E
- 32.1x
- P/B
- 1.78x
- ROE
- 9.5%
- Dividend yield
- -
- Fundamental score
- 2.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 302550.KQ undervalued?
Graham number302550.KQ trades 59.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Remed Co.Ltd fundamental analysis
10 of 22 checks passedROE 0/2
Low return on equity (9.5%), below 10%.
ROA 1/1
Return on assets (6.8%) is above the industry median (6.2%).
Profit Consistency 2/2
Profitable for 5 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-92.6%) is below the industry median (0.5%).
Revenue Growth 1/2
Revenue grew 4.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (7.0%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (32.1x) is above the market median (11.3x).
PE vs Industry 0/1
PE (32.1x) is above the industry median (7.6x).
PBV 0/1
Price to book (1.8x) is above the industry median (0.7x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 57.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Remed Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Remed Co.Ltd
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells, and contraction and relaxation of muscles, as well as core muscle strengthening…
Full company profileRemed Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Remed Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 6.24B | 8.00B | 18.6B | 16.6B | 20.2B | 21.4B | 18.5B | 25.6B | 24.5B | 29.1B |
| Gross Profit | 3.41B | 4.00B | 10.7B | 8.64B | 10.4B | 11.2B | 9.03B | 14.2B | 14.1B | 16.5B |
| Operating Income | 337M | -829M | 4.31B | 1.68B | 1.15B | 1.66B | 1.13B | 852M | 726M | 3.26B |
| EBITDA | - | - | - | - | - | 6.28B | 3.18B | 10.5B | 1.99B | 5.72B |
| Net Income | 36.2M | -7.38B | 4.36B | -1.83B | 752M | 4.00B | 797M | 7.17B | 526M | 3.63B |
| EPS | 18 | -1,429 | 749 | -301 | 123 | 653 | 26 | 234 | 17 | 119 |
| Balance Sheet | ||||||||||
| Total Assets | 12.6B | 21.5B | 34.9B | 73.5B | 77.2B | 78.1B | 55.1B | 59.1B | 53.9B | 53.8B |
| Total Liabilities | 8.41B | 10.6B | 10.3B | 48.7B | 51.1B | 48.2B | 24.3B | 18.8B | 14.4B | 16.6B |
| Shareholders' Equity | 4.19B | 10.9B | 24.6B | 24.8B | 26.1B | 29.9B | 30.8B | 40.2B | 40.1B | 38.3B |
| Cash & Short-term Investments | 2.86B | 6.28B | 15.2B | 41.6B | 36.4B | 30.6B | 6.25B | 10.7B | 8.47B | 9.00B |
| Total Debt | - | - | 5.86B | 18.9B | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 66.7M | -318M | 3.22B | 2.59B | -3.49B | 5.21B | 3.50B | 1.24B | 2.40B | 3.96B |
| Capital Expenditure | 769M | 5.01B | 2.01B | 680M | 4.88B | 4.77B | 894M | 609M | 869M | 4.16B |
| Free Cash Flow | - | - | - | -6.27B | -4.12B | -5.62B | 2.60B | 636M | 1.53B | -198M |
| Ratios | ||||||||||
| ROE | 0.9% | -67.4% | 17.7% | -7.4% | 2.9% | 13.4% | 2.6% | 17.8% | 1.3% | 9.5% |
| ROA | 0.3% | -34.3% | 12.5% | -2.5% | 1.0% | 5.1% | 1.4% | 12.1% | 1.0% | 6.8% |
| Net Profit Margin | 0.6% | -92.2% | 23.5% | -11.0% | 3.7% | 18.7% | 4.3% | 28.1% | 2.1% | 12.5% |
| Debt to Equity | - | - | 0.24x | 0.76x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Remed Co.Ltd dividends
Remed Co.Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 5:1 on Dec 26, 2023.
Who owns Remed Co.Ltd
- Insiders 39.46%
- Institutions 0.00%
- Public & others 60.54%
- Shares outstanding 29.8M
- Free float 18.6M
Remed Co.Ltd company profile
- Company name
- Remed Co.Ltd
- Ticker
- 302550.KQ
- ISIN
- KR7302550009
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 88
- Fiscal year end
- December
- Address
- No. 301- 303, 187 Techno2-ro, Daejeon, South Korea, 34025
- Phone
- 82 3 1606 5755
- Website
- remed.kr
About Remed Co.Ltd
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells, and contraction and relaxation of muscles, as well as core muscle strengthening magnetic stimulation to enable building toned and shaped muscles. In addition, the company provides extracorporeal shock wave therapy; and technology to activate the sensory function of prostate and strengthen the pelvic floor muscle by stimulating them with electromagnetic pulse. The company was formerly known as CR Technology Co., Ltd. and changed its name to Remed Co., Ltd. in 2013. Remed Co., Ltd. was founded in 2003 and is headquartered in Daejeon, South Korea.
Remed Co.Ltd management
2- Mr. Geun-Yong LeeChief Executive Officer · born 1968
- Tae-gun KimChief Technology Officer